Eli Lilly Eyes India for Global Drug Supply Hub

Eli Lilly intends to establish India as a pivotal center within its worldwide supply chain, reinforcing its commitment to a $1 billion investment in the country's contract manufacturing sector. The pharmaceutical giant sees potential for exporting drugs produced in India to markets across the globe.

Mounjaro, Eli Lilly's prominent weight-loss medication, experienced a significant surge in sales in India, doubling within months of its launch and quickly becoming its highest-selling medicine by value. This success highlights the increasing demand for obesity treatments in India.

Beyond its existing offerings, Eli Lilly plans to introduce additional products to the Indian market, including its Alzheimer's drug donanemab and novel obesity treatments like the experimental oral drug orforglipron, pending regulatory approvals. The company is also focusing on expanding Mounjaro's reach through digital and social media campaigns, particularly in smaller Indian cities, and has broadened its distribution network through partnerships with firms like Cipla and digital health platforms.